# A Study of TFX05-01 in Patients With Advanced Solid Tumors

> **NCT05434299** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Zhejiang Yangli Pharmaceutical Technology Co., Ltd.** · enrollment: 36 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** TFX05-01

## Key facts

- **NCT ID:** NCT05434299
- **Lead sponsor:** Zhejiang Yangli Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-05
- **Primary completion:** 2024-12
- **Final completion:** 2025-12
- **Target enrollment:** 36 (ESTIMATED)
- **Last updated:** 2023-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05434299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05434299, "A Study of TFX05-01 in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05434299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*